SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Alembic Pharmaceuticals informs about press release

18 Nov 2016 Evaluate

Alembic Pharmaceuticals has informed about a Press Release dated November 18, 2016, title ‘Alembic Pharmaceuticals receives USFDA Approval for Telmisartan and Amlodipine Tablets’.

The above information is a part of company’s filings submitted to BSE.

Alembic Pharma Share Price

753.15 -5.85 (-0.77%)
21-Apr-2026 09:29 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1677.45
Dr. Reddys Lab 1229.00
Cipla 1230.00
Zydus Lifesciences 932.00
Lupin 2333.50
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×